Why Gene Therapy Is Still So Hard to Manufacture at Scale | Phillip Ramsey

Why is gene therapy still so difficult to manufacture at scale after decades of progress?

Phillip Ramsey, Chief Technical Officer at Sangamo Therapeutics, joins BioTalk Unzipped for a candid conversation about one of the central challenges facing advanced therapies: turning extraordinary science into reproducible, scalable medicines.

Thank You to Our Sponsors

Leucentra - https://leucentra.com/

Inspired by Science. Empowered by IT. Leucentra provides specialized IT consulting and services for life sciences and healthcare, helping organizations use technology more effectively to support innovation.

TruTechnologies - https://trutechnologies.ai/

Clinical Trial Execution, Live. TruTechnologies provides live clinical trial execution technology that gives sponsors greater visibility into protocol activities, samples, and study data as they happen.

About This Episode

Recorded onsite at the AAPS National Biotechnology Conference in Boston, Phillip explains why gene therapy manufacturing has not yet reached the maturity of monoclonal antibody production.

As technologies have evolved across retroviral vectors, lentiviral vectors, adenovirus, AAV, lipid nanoparticles, and other advanced modalities, development teams have repeatedly been required to rethink fundamental manufacturing and analytical questions.

Phillip discusses why analytics are critical, why experience across multiple manufacturing lots and products matters, and why there simply is no shortcut to developing the scientific knowledge necessary to manufacture advanced therapies reliably.

He also reflects on the uncertainty of biotechnology.

Early in his career, Phillip was walking down a hallway when his CFO asked if he had cashed his paycheck.

When he said no, she told him not to.

It's a remarkable story that captures something rarely discussed about biotechnology: behind transformative science are people willing to operate through considerable uncertainty while trying to build something that has never existed before.

Gregory and Phillip Discuss

• Viral vector manufacturing and scale-up

• Why analytics are essential to gene therapy development

• AAV manufacturing challenges

• Lentiviral vectors and other evolving delivery technologies

• Lipid nanoparticles and changes in advanced therapy manufacturing

• Why gene therapy cannot simply adopt the established monoclonal antibody manufacturing playbook

• Building process knowledge across lots and products

• Career resilience in biotechnology

• Progress across AAV, CAR-T, and other advanced therapies

• Gene therapy affordability

• The importance of therapeutic durability

• Outcomes-based payment models for advanced therapies

Phillip's message for scientists and industry leaders is straightforward: don't assume the manufacturing problem has already been solved simply because a technology has existed for decades.

The field is still evolving, and some knowledge cannot be shortcut.

About Phillip Ramsey

Phillip Ramsey is Chief Technical Officer at Sangamo Therapeutics and brings more than 35 years of experience across biotechnology and pharmaceutical manufacturing, technical development, operations, quality, and advanced therapies.

Connect with Phillip Ramsey:

https://www.linkedin.com/in/phillip-ramsey-a2074711/

Sangamo Therapeutics:

https://www.sangamo.com/

Connect With BioTalk Unzipped

Gregory Austin on LinkedIn:

https://www.linkedin.com/in/gregoryaustin1/

Dr. Chad Briscoe on LinkedIn:

https://www.linkedin.com/in/chadbriscoe/

BioTalk Unzipped:

https://www.biotalkunzipped.com/

BioTalk Unzipped unzips, unlocks, and uncovers the stories behind medical progress through conversations with scientists, executives, entrepreneurs, and innovators advancing biotechnology, pharmaceuticals, and medical technology.

Recorded onsite at the AAPS National Biotechnology Conference in Boston.

Special thanks to AAPS and Rebecca Stauffer for supporting the BioTalk Unzipped interview series.